文献库搜索 | GeneLibs

Ding(KX),Zhang(ZL),Lu(YP),Cao(YL),Zhang(SQ... Animals (Basel) 2026-08-12

...MOSs for an 8-week feeding trial. The results demonstrated that MOS supplementation significantly improved growth perfor...

Neesanun(S),Patumanond(J) Asian Pac J Cancer Prev 2026-08-01

...mOS) was 4.73 months (95% CI: 3.68-6.51). Eight independent predictors were identified: ECOG performance status, Child-P...

Ciardiello(D),Martini(G),Pietrantonio(F),A... ESMO Gastrointest Oncol 2026-09-00

...mOS) 12.9 months (95% CI 11.1-not evaluable). Cetuximab activity was retained regardless of clinical factors. Patients t...

Fan(H),Feng(X),Wei(R),Zhang(X),Li(T),Liu(L... Ther Adv Hematol None

...mOS) was not reached (NR). The mPFS was NR, 22.5, and 10.1 months (P=0.178), and the mOS was NR, NR, and 11.6 months (P=...

Bitting(RL),Tseng(CL),Giagtzis(A),Wyatt(AW... Clin Genitourin Cancer 2026-08-05

...mos). Black patients with CDK12 alterations had longer OS than those without (21.4 vs. 12.2 mos). In this real-world coh...

Tan(CK),Vogel(A),Wong(YF),Ho(GF),Zhou(J),A... ESMO Open 2026-08-00

...MOS)], the Philippines (Philippine Society of Medical Oncology), Singapore (Singapore Society of Oncology), Taiwan (Taiw...

Yang(Y),Jiang(L),Zhang(G),Li(K),Li(D) Front Immunol 2026-00-00

...mOS) 12.74 months vs monotherapy subgroup 10.60 months; single-arm combination cohort mOS 16.96 months). The most common...

Han(Z),Ren(Y),Zhang(T),Zhang(X),Zhang(R),C... ACS Sens 2026-08-28

...MOs possess enhanced conductivity contributed by metal oxides, high mass transfer efficiency enhanced by the mesoporous ...

Ghoshal(T),Singh(S),Neill(H),Gity(F),Roy(J... ACS Appl Mater Interfaces 2026-08-31

...MOS capacitor characterization establish the quality of the fabricated multilayer stack and its charge trapping behaviou...

Zheng(T),Liu(Z),Lu(Y),Zhou(H),Yang(K),Zhou... ACS Sens 2026-08-31

...MOS) is a promising route for enhance H2 sensing; however, achieving high atomic utilization at low noble metal loading ...